Awakn Life Sciences announces closing a a CAD $3.25 million private placement, with units priced at $1.60 along with a half-warrant with an exercise price of $2.20.

Wesana Health reports positive treatment results in combining traditional antidepressants with psilocybin-based therapy.

Revitalist Lifestyle and Wellness announces a new initiative focusing on providing access to mental health therapies for veterans and first-responders.

The psychedelic medicine industry is growing. There was a wave of new psychedelic firms going public, with big names like MindMed and Atai Life Sciences listing on major stock exchanges like the NASDAQ, and increased acceptance of psychedelics by institutional investors.

Novamind announces it will most MindMed’s Phase IIb clinical trial of LSD-based therapy for generalized anxiety disorder (GAD).

Ketamine Wellness Centers, a subsidiary of Delic Holdings, announces the grand opening of its 13th ketamine clinic.

MINDCURE announces the completion of its strategic review and new cost saving measures.

Awaken receives regulatory approval to begin ketamine-based therapies in its flagship London mental health clinic.

Thanks to the advance of psychedelic medicine, “brain injury awareness” is about more than highlighting a problem. It’s also about new hope for sufferers.